International Finance Corporation came to CMBA to survey the policy
2014-12-23
International Finance Corporation (IFC)
of world bank group came to CMBA to survey the project of CMBA’s member and
consult the situation of policy of Chinese biological medicine industry on
December 5, 2014. The CMBA member is Sengen Biotech company. They introduced
their series product of insulin (the technical information and project
progress) to IFC. IFC also introduced that they look for the project that have
long term expect and good social effect. They will have further interaction in
the next. After the introductions, IFC consult issues related to the Chinese
biomedicine industry, CMBA vice president, Ms. Li Shaoli introduced that the
biomedicine industry had already been enlisted in the national strategic development.
General secretary, Mr. Wu Zhaohui introduced pointed out that the orientation
of policy had altered from focusing on generics medicine into focusing
on novel medicine. He also explained the national vital novel medicine program
and the implementation of bio similar policy making. IFC also consulted the
time and process of bio similar medicine approval. The former experts from center
for drug evaluation, CFDA explained that the time should been based on the type
of drug and the government is trying to accelerate the approve efficiency. The
experts expressed their opinion that the CFDA will issue the bio similar guideline
in recent time. Currently, the draft version of guideline is under the advice
recruitment. This meeting promote the communication of investment company and
our member, providing clear consult information to IFC.
